Mylan Inc. today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, received final approval from the U.S. FDA on December 29, for its Abbreviated New Drug Application for Stavudine Capsules USP, 15 mg, 20 mg, 30 mg and 40 mg.
The details can be read here.
No comments:
Post a Comment